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and those with enlarged (10 mm) but
PET negative lymph nodes. All pa-
tients in whom mediastinal staging is
negative go forward for surgical resec-
tion with systematic lymph node sam-
pling or dissection. Data from this
study may also help to address the
issue about what should be done for
those with enlarged but PET negative
mediastinal nodes.
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Pulmonary Tumor
Embolism
To the Editor:
We read with interest the recent
report by Kridel et al.1 describing a
rare case of pulmonary tumor embo-
lism (PTE) with elevated level of se-
rum D-dimer causing an acute right
heart failure.
We would like to add the follow-
ing comment. The clinical entity of pul-
monary tumor thrombotic microangi-
opathy (PTTM) that is a distinct form of
PTE is not adequately discussed in their
manuscript. PTTM, first reported by von
Herbay in 1990, is characterized by fi-
brocellular intimal proliferation of small
pulmonary arteries and arterioles in pa-
tients with cancer (especially adenocar-
cinoma).2 They stressed that the mor-
phologic findings in PTTM were
different from microscopic PTE as re-
ported previously.3 The prominent fea-
ture of PTTM is that tumor emboli
induce both local activation of the coag-
ulation system and fibrocellular intimal
proliferation, leading to the luminal ste-
nosis or occlusion in the affected ves-
sels. Clinically, patient with PTTM pre-
sents progressive dyspnea and an acute
right heart failure due to pulmonary hy-
pertension, and its prognosis is quite
dismal. A definitive diagnosis of PTTM
based on surgical lung biopsy is quiet
difficult antemortem due to its aggres-
siveness. Miyano et al.4 reported a suc-
cessfully diagnosed and treated case of
PTTM of that patient with a history of
gastric adenocarcinoma presented a dry
cough and showed an elevated level of
serum D-dimer (8900 g/L). As the au-
thors discussed, the elevation of D-dimer
level should be explained by the activa-
tion of coagulation, which is a specific
feature in PTTM.
We therefore believe that this case
is consistent with PTTM rather than
PTE in terms of the abnormality of co-
agulation cascade.
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In Response:
We thank Shigematsu et al. for
drawing our attention on the entity of
pulmonary tumor thrombotic microangi-
opathy (PTTM) that was first described
by von Herbay et al.1 These authors
pointed out that the morphologic find-
ings are different in PTTM and pulmo-
nary tumor embolism (PTE), as illus-
trated by the comparison of their cases
and those of previous descriptions.
PTTM is characterized by activation of
the coagulation cascade induced by tu-
mor cells in the lung vasculature, result-
ing in obstructive thrombosis and inti-
mal proliferation. PTE was described by
Winterbauer et al.2 as pulmonary vascu-
lar obstruction by tumor emboli.
In our case report,3 the lung his-
tology revealed that, whereas most of
small lung arteries were entirely occluded
with tumor emboli, only a minority of
vessels was affected both by tumor emboli
and thrombi. We therefore believe that our
case report is compatible with descriptions
of PTE rather than PTTM, despite the
elevated D-dimer level.
We doubt that the distinction be-
tween the two entities can currently be
established in a clear-cut manner. In-
deed, Kane et al.4 have reported that
tumor emboli to the lung vasculature are
frequently associated with thrombi and
later descriptions of PTE also high-
lighted that thrombosis and intimal
proliferation often accompany tumor
emboli.5,6 Further research seems thus
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necessary to refine the diagnostic cri-
teria of both entities.
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Thymic Small Cell
Carcinoma Shows
Marked Response to
Amrubicin
To the Editor:
Thymic small cell carcinoma (small
cell carcinoma, neuroendocrine type ac-
cording to the World Health Organiza-
tion histologic classification) is a rare
aggressive mediastinal neoplasm, and
the optimal treatment remains unde-
fined. In this report, we describe a case
of thymic small cell carcinoma that
showed marked response to second-line
chemotherapy with single-agent amrubi-
cin (AMR), a synthetic anthracycline
analogue and potent deoxyribonucleic
acid topoisomerase II inhibitor.
A 57-year-old man was diagnosed
to have thymic small cell carcinoma
with pericardial sac invasion, pleural
dissemination and pulmonary metastasis
(stage IVb according to the classifica-
tion proposed by Masaoka et al). The
patient was initially treated by combina-
tion chemotherapy with paclitaxel and
carboplatin, in September 2006. Four
cycles of the chemotherapy were admin-
istered, and partial response was con-
firmed. However, regrowth of the mass
in the anterior mediastinum and that of
the pulmonary metastasis were observed
(Figure 1A). In addition, the serum lev-
els of neuron-specific enolase (80 ng/
ml) and progastrin-releasing peptide
(ProGRP, 515 ng/ml) were also elevated
(Figure 2). For the treatment in the sec-
ond-line setting, AMR administration
was begun in May 2007 at the dose of 40
mg/m2/d on days 1 to 3, every 3 weeks.
A chest computed tomography after four
cycles of AMR treatment demonstrated
a marked reduction in the size of the
anterior mediastinal mass and that of the
pulmonary metastasis, confirming par-
tial response (Figure 1B). Both the se-
rum neuron-specific enolase and Pro-
GRP levels decreased to their respective
normal ranges (Figure 2). The adverse
events related to AMR were no higher
than grade 1 in severity, according to
the Common Toxicity Criteria for Ad-
verse Events, Version 3.0 grading sys-
tem, proposed by the National Cancer
Institute. Only grade 1 neutropenia
and leukopenia were observed. After
seven cycles of AMR treatment, the
chest computed tomography obtained
in January 2008 revealed regrowth of
the anterior mediastinal mass and the
serum level of ProGRP was also ele-
vated. Although, subsequent treatments
Disclosure: The authors declare no conflicts of
interest.
Copyright © 2009 by the International Association
for the Study of Lung Cancer
ISSN: /09/0406-0778
FIGURE 1. A, Computed tomography before administration of AMR. B, Marked
diminution in size of the mass in the anterior mediastinum.
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FIGURE 2. Clinical course and serum levels of neuron specific enolase (NSE) and
progastrin-releasing peptide (ProGRP).
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